











#	Video	Narration
1		<p>Contribute toward the improvement of people's health and progress in society through the development of innovative products.</p> <p>As a pioneer in hormone preparations, and with over a century of innovation behind us, this is the ASKA Pharmaceutical Holdings' corporate philosophy.</p>
2		<p>Our story began in 1920, in Yokohama.</p> <p>Our founder, Yasohachi Yamaguchi, saw potential where others saw waste, recognizing new value in animal-derived materials discarded by food production.</p> <p>He established the Teikoku Hormone Research Institute launching the research, development, and production of hormone-based medicines.</p> <p>This marked the beginning of ASKA Pharmaceutical.</p> <p>Since then, we have continued forward with a clear sense of purpose, and a mission directly connected to life and health.</p> <p>In 1945, we became Teikoku Hormone Mfg. Co., Ltd., building trust as a pioneer in hormone preparations through our unwavering commitment to healthcare.</p>
3		<p>Following our stock listing in 1955, we accelerated our growth.</p> <p>We established our position as a specialty pharma company, focusing on key therapeutic areas including obstetrics and gynecology, internal medicine, and urology.</p> <p>At the same time, we expanded into new fields including animal health, clinical testing, and medical devices.</p>
	<p>NEXT</p>	

#	Video	Narration
4		<p>In 2005, a merger with Grelan Pharmaceutical Co. Ltd led to the formation of ASKA Pharmaceutical Co., Ltd.</p> <p>By combining our expertise in hormone preparations with new technologies and talent, we broadened the scope of our business.</p> <p>Then, in 2021, building on a century of history, as a new step forward toward becoming a total healthcare company, we transitioned to a holding company structure, as ASKA Pharmaceutical Holdings.</p> <p>This laid the foundation for the company's next stage of growth.</p>
5		<p>And now, we look to the future.</p> <p>ASKA Vision 2035.</p> <p>From Japan, to Asia, and to the world.</p> <p>As a specialty healthcare company, we will continue delivering new value to society.</p>
6		<p>While honoring our strengths we have cultivated,</p> <p>we hope to be a company</p> <p>providing new values to the society</p> <p>This idea is developed in our long-term vision</p> <p>representing directions we pursue.</p> <p>Amid major changes in the society and healthcare environments,</p> <p>we have decided to change for ourselves.</p> <p>Currently, we are steadily advancing initiatives</p> <p>to bring our vision to life.</p>
	<p>NEXT</p>	

#	Video	Narration
7		<p style="text-align: center;">Mid-Term Management Plan 2028</p> <p style="text-align: center;">As a first step toward realizing this long-term vision, beginning in fiscal 2026, we have established our Mid-Term Management Plan 2028.</p> <p style="text-align: center;">By balancing the steady growth of existing businesses with the development of future growth drivers, we aim to build a foundation for sustainable earnings.</p>
8		<p style="text-align: center;">To drive growth, we have defined five core business pillars, and are focusing our resources accordingly.</p>
9		<p style="text-align: center;">(1) Domestic Pharmaceuticals</p> <p style="text-align: center;">In Japan, we continue to deepen our expertise in specialty areas centered on obstetrics and gynecology, and thyroid disorders.</p> <p style="text-align: center;">Building on our long-standing presence in clinical settings, we address health challenges related to biological differences.</p> <p style="text-align: center;">(2) Drug Discovery</p> <p style="text-align: center;">Strengthening our drug discovery capabilities, we are enhancing our global competitiveness through partnerships, and co-development of proprietary compounds.</p> <p style="text-align: center;">Maximizing the value of our research, we will create opportunities for mid- to long-term growth and sustained revenue.</p>
	NEXT	

#	Video	Narration
10		<p style="text-align: center;">(3) Global Business</p> <p style="text-align: center;">With a focus on Southeast Asia in particular, we are accelerating our expansion overseas, strengthening our presence in new markets, and building a global foundation for growth.</p> <p style="text-align: center;">(4) Animal Health</p> <p style="text-align: center;">Contributing to a society where people and animals can thrive together, we are expanding our business by leveraging our strengths.</p> <p style="text-align: center;">(5) Testing & Around-the-Pill</p> <p style="text-align: center;">Through advanced analytical technologies, we are extending value beyond pharmaceuticals, into adjacent areas that support healthcare.</p>
	<p>NEXT</p>	

#	Video	Narration
11	 <p>With strong execution capabilities, enhancing management sophistication</p>	<p>Two Foundations</p> <p>Supporting these businesses are two key foundations.</p> <p>Financial strategy focused on capital efficiency, and a strengthened management base built on governance, talent, digital transformation, and ESG.</p> <p>Together, these initiatives enhance execution and drive more sophisticated management.</p>
12		<p>By leveraging our advanced expertise, we are committed to shaping the future.</p> <p>As a specialty healthcare company, and as a leader in women's health, we continue to deliver comprehensive healthcare.</p>
13		<p>For a Healthy Tomorrow, and Future.</p>
	<p>END</p>	